Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins.

Journal of pharmaceutical and biomedical analysis - 25 Oct 2022

Liu Tao, Li Yantao, Xu Jin, Guo Qingcheng, Zhu Lei, Fu Tuo, Li Jun, Zhang Dapeng, Qian Weizhu, Zhou Xinli, Guo Huaizu, Hou Sheng

Abstract excerpt

The early intervention is essential, and later development cannot compensate for this initial generation of an antibody drug. Especially for sequence variants (SVs), should cause concern during the early bioprocess development. The advancement of bioprocess development is paralleled by development of state-of-the-art analytical methods that will provide further information. In the present study, a mass...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Quality Control

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 36030755
DOI: 10.1016/j.jpba.2022.115018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins.PMID 36030755Read ↗

Challenges and Strategies for a Thorough Characterization of Antibody Acidic Charge VariantsSemantic proximity Read ↗

Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study.Semantic proximity Read ↗

Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.Semantic proximity Read ↗

An optimized approach to the rapid assessment and detection of sequence variants in recombinant protein products.Semantic proximity Read ↗

The Challenges and Breakthroughs in the Development of Diagnostic Monoclonal AntibodiesSemantic proximity Read ↗

Integrating Intact Mass Analysis and Middle-Down Mass Spectrometry Approaches to Effectively Characterize Trastuzumab and Adalimumab Structural HeterogeneitySemantic proximity Read ↗

Mass Spectrometry for the Analysis of Payloads and Related Impurities in Antibody–Drug ConjugatesSemantic proximity Read ↗

Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes?Semantic proximity Read ↗

Impact of mammalian cell culture conditions on monoclonal antibody charge heterogeneity: an accessory monitoring tool for process developmentSemantic proximity Read ↗

Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical DiscoverySemantic proximity Read ↗

Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based DetectionSemantic proximity Read ↗

Simplified and Rapid Workflow Enhances Throughput of <i>De Novo</i> Sequencing of COVID-19 Neutralizing AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.